We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+41.74%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$45.1M
Cap. Flow
-$1.39M
Cap. Flow %
-0.44%
Top 10 Hldgs %
73.5%
Holding
26
New
1
Increased
6
Reduced
2
Closed
5

Top Buys

1
MPLT
MapLight Therapeutics
MPLT
+$15.9M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$5.03M
3
BHVN icon
Biohaven
BHVN
+$3.22M
4
TARA icon
Protara Therapeutics
TARA
+$3.17M
5
TECX
Tectonic Therapeutic
TECX
+$1.77M

Top Sells

1
DNTH icon
Dianthus Therapeutics
DNTH
+$14.4M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$9.01M
3
ALEC icon
Alector
ALEC
+$2.95M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$2.53M
5
ADVM
Adverum Biotechnologies
ADVM
+$2.45M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$267M
$41.7M 13.11%
4,056,379
-200,000
-5% -$1.69M
CAMP icon
2
CAMP4 Therapeutics
CAMP
$203M
$36M 11.31%
5,869,091
– –
TYRA icon
3
Tyra Biosciences
TYRA
$1.88B
$27.1M 8.51%
1,029,298
+90,000
+10% +$1.65M
VRDN icon
4
Viridian Therapeutics
VRDN
$1.99B
$22.9M 7.21%
736,595
– –
PHVS icon
5
Pharvaris
PHVS
$2.35B
$22.1M 6.96%
797,600
– –
ERAS icon
6
Erasca
ERAS
$6.6B
$20.1M 6.32%
5,405,404
– –
EYPT icon
7
EyePoint Inc
EYPT
$1.09B
$19.2M 6.03%
1,050,000
– –
MPLT
8
MapLight Therapeutics
MPLT
$1.69B
$16.7M 5.25%
+950,011
New +$15.9M
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
$14.5M 4.57%
580,945
-100,000
-15% -$2.53M
CLDX icon
10
Celldex Therapeutics
CLDX
$2.78B
$13.5M 4.25%
497,270
– –
TECX
11
Tectonic Therapeutic
TECX
$578M
$12.7M 3.98%
606,660
+95,000
+19% +$1.77M
ELVN icon
12
Enliven Therapeutics
ELVN
$3.63B
$11.9M 3.74%
772,477
– –
ARTV
13
Artiva Biotherapeutics
ARTV
$439M
$10.1M 3.17%
2,353,304
– –
SRZN icon
14
Surrozen
SRZN
$241M
$8.76M 2.75%
387,500
+77,500
+25% +$1.25M
BHVN icon
15
Biohaven
BHVN
$2.13B
$8.34M 2.62%
738,972
+260,000
+54% +$3.22M
TARA icon
16
Protara Therapeutics
TARA
$229M
$7.3M 2.3%
1,369,782
+569,782
+71% +$3.17M
GHRS icon
17
GH Research
GHRS
$2B
$7.27M 2.29%
572,665
– –
SKYE icon
18
Skye Bioscience
SKYE
$22.1M
$7.26M 2.28%
9,681,763
– –
ZNTL icon
19
Zentalis Pharmaceuticals
ZNTL
$325M
$5.33M 1.68%
3,947,913
+3,457,913
+706% +$5.03M
SLN
20
Silence Therapeutics
SLN
$516M
$2.9M 0.91%
476,200
– –
RLYB icon
21
Rallybio
RLYB
$84.7M
$2.49M 0.78%
453,841
– –
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
– –
-541,666
Closed -$2.45M
ALEC icon
23
Alector
ALEC
$163M
– –
-995,841
Closed -$2.95M
DNTH icon
24
Dianthus Therapeutics
DNTH
$5.21B
– –
-365,053
Closed -$14.4M
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
– –
-52,200
Closed -$405K
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
BWM
BNC Wealth Management Beaverton, Oregon $360M AUM 49.82% 1-Year Est. Return
LC
Legacy CG Plano, Texas $360M AUM 17.55% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
PWM
Proathlete Wealth Management Boca Raton, Florida $361M AUM 17.13% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return

5AM Venture Management's Q4 2025 Portfolio in Review

As of Q4 2025, 5AM Venture Management held 26 positions worth $318M, up 17% from $273M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

5AM Venture Management's Q4 2025 filing shows 1 new, 6 increased, 2 reduced and 5 closed positions. Its largest new stake was MapLight Therapeutics: 950,011 shares worth $16.7M. The largest sale was Dianthus Therapeutics, an estimated $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q4 2025 buy was MapLight Therapeutics: 950,011 shares worth $16.7M.
  • 5AM Venture Management added most to Zentalis Pharmaceuticals in Q4 2025, an estimated $5.03M increase.
  • 5AM Venture Management's biggest Q4 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $2.53M.
  • 5AM Venture Management fully exited Dianthus Therapeutics in Q4 2025, selling an estimated $14.4M.
  • 5AM Venture Management's ten largest holdings make up 74% of its $318M portfolio in Q4 2025.
  • 5AM Venture Management opened 1 new position and closed 5 in Q4 2025.
  • 5AM Venture Management's portfolio value rose 17% quarter-over-quarter to $318M.

Based on 5AM Venture Management's 13F filing for Q4 2025, filed 17 Feb 2026.